EGFR and non-small cell lung carcinoma: Taken “erlotinib and vorinostat,” “erlotinib and dactolisib,” “erlotinib and MK-2206” as examples, they have significantly high synergy scores in EGFR mutated cell lines than those without EGFR mutations, whether in NSCLC cell lines or in all cell lines (Fig. 6C, Supplementary Fig. S4B and C).